Biogen Idec's Commitment to MS Demonstrated Through Significant Scientific ... MarketWatch (press release) About DAC HYP Daclizumab high-yield process (DAC HYP) is a subcutaneous formulation of daclizumab in late-stage clinical development for the treatment of RRMS, the most common form of MS. DAC HYP is a humanized monoclonal antibody that binds to ... |
